NCT02369796View on ClinicalTrials.gov

A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism

PHASE2TerminatedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

November 30, 2015

Conditions

Hypogonadotropic Hypogonadism

Interventions

DRUG

TAK-448

TAK-448 solution for subcutaneous injection

Trial Locations (1)

OX3 7LJ

Oxford

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY